Primary Focal Hyperhidrosis

    • Primary focal hyperhidrosis is a chronic disorder of an abnormally high amount of perspiration which is in excess of that required for natural thermal regulation. It has a very negative impact on quality of life from a social, emotional, and psychological perspective.
    • Primary focal hyperhidrosis generally occurs in multiple locations on the body (Axillary, Palmar, Plantar, Trunk / Inguinal, Craniofacial) with one location being more severe than the others

Secondary (generalized) Hyperhidrosis

    • Secondary hyperhidrosis refers to excessive sweating caused by another medical condition or side effect of a medication (e.g., menopause, diabetes, obesity, anti-depressants)
    • Unlike primary hyperhidrosis, patients with secondary hyperhidrosis more often experience generalized hyperhidrosis (excessive sweating on larger parts of the body or overall body)
  • Hyperhidrosis is considered more detrimental to daily function and more difficult to conceal than many other dermatologic conditions; current treatments are minimally effective, inconvenient and/or uncomfortable.
  • In the United States alone, there are about 11 million people suffering from primary focal hyperhidrosis and over half of them remain undiagnosed or have not discussed their condition with a healthcare professional.  In addition, there are about 7 million people suffering from secondary hyperhidrosis.
  • The most commonly prescribed treatments tend to be antiperspirants. While these products may temporarily help with mild symptoms, their application tends to be limited by modest efficacy especially in cases suffering from moderate to severe hyperhidrosis.
  • While muscarinic antagonists have demonstrated efficacy in clinical trials, they have significant side effects, most commonly dry mouth, which decreases patient compliance with treatment resulting in poor clinical outcomes.

Overall, given the limitations of options available in the market today, we believe there is a significant unmet need in a large patient population.